• AAPL 169.89
  • TSLA 170.18
  • AMZN 173.67
  • MSFT 399.04
  • INTC 35.11
  • EURUSD 1.0725
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ACIU.NASDAQ

AC Immune Ltd (ACIU NASDAQ) stock market data APIs

$2.35 0.06(2.6%) as of April 25, 2024

AC Immune Ltd Financial Data Overview

2.29
2.35
-
2.4
2.27
1.78-5.14
229 M
98 899 K
14 801 K
1.013
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ACIU',
Type: 'Common Stock',
Name: 'AC Immune Ltd',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: 'CH0329023102',
CUSIP: 'H00263105',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2016-09-23',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

AC Immune Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 14 801 K
  • EBITDA -51 952 000
  • Earnings Per Share -0.7
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get AC Immune Ltd Earnings via APIs

  • Latest Release 2024-04-26
  • EPS/Forecast -0.15

Get AC Immune Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get AC Immune Ltd latest news via APIs

Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround

A downtrend has been apparent in AC Immune (ACIU) lately with too much selling pressure. The stock has declined 35.7% over the past four weeks. However, given the fact that it is now in oversold terri...

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune SA AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunothe...
Do you have any questions?
support@eodhistoricaldata.com